Market Overview

QIAGEN Creates Collaboration with Japan's Largest Clinical Laboratory Testing Company, SRL, to Accelerate Launch of Companion Diagnostics


Day-one lab readiness speeds commercialization and reimbursement in
personalized medicine

QIAGEN N.V. (NYSE:QGEN, Frankfurt Prime Standard: QIA)) today announced
a collaboration with SRL, Inc., the largest clinical testing laboratory
company in Japan, to prepare for introduction of new companion
diagnostics simultaneous with new drug approvals. The non-exclusive
master collaboration agreement for clinical laboratory research services
will enable rapid implementation by SRL of QIAGEN´s companion diagnostic
workflows upon approval of the drugs and tests by Japan's Pharmaceutical
and Medical Devices Agency (PMDA). Several tests QIAGEN is co-developing
with pharmaceutical partners are expected to enter registration in Japan
in the coming years.

QIAGEN's Day-One Lab Readiness initiative with SRL includes strategic
planning for market access to companion diagnostics, filing for
reimbursement, and alignment of medical communication by SRL, QIAGEN and
pharmaceutical partners. The agreement will cover a range of QIAGEN
companion diagnostics, including real-time polymerase chain reaction
(PCR) and next-generation sequencing (NGS) solutions for Personalized
Healthcare. Initial projects involve QIAGEN companion diagnostics paired
with new drugs under development in Japan for solid tumors and leukemia.

Please find the full press release here

View Comments and Join the Discussion!